<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
Nov 14, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29th Annual Healthcare Conference at 2:50 p.m. ET on Wednesday, November...
Nov 7, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017. "Third quarter results were in line with our expectations, despite wea...
Nov 1, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating Officer, John Onopchenko. The awards were approved by Endologix's ...
Oct 26, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel 2017 Healthcare Conference at 2:00 ...
Oct 19, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October 30, 2017. Mr. Onopchenko will be responsible for managing ...
Oct 10, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017. The Company's management wi...
Oct 6, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to commence a confirmatory cli...
Sep 21, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix® EndoVascular Aneurysm Sealing System ("Nellix") with the refined Indications for Use (IFU). Nellix is being s...
Sep 11, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. ("JLL") pertaining ...
Aug 17, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD (Looking at Evar Outcomes by Primary Analysis of Randomized Data) clinical study. LEOPARD is the first and onl...
Aug 2, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2017. "While we are pleased with the overall results in the second quarter, the ...
Jul 12, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2017 after the market close on Wednesday, August 2, 2017. The Company's management wi...
Jul 10, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Canaccord Genuity 37th Annual Growth Conference at...
Jun 3, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that prospectively enrolled patients with abdominal aortic aneu...
May 31, 2017
First Prospective Clinical Trial to Evaluate Endovascular Aneurysm Repair (EVAR) in Women IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation...
Page:
2
...
16
Next Last
 
= add release to Briefcase